advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (10)
Showing records 1 to 10
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation51132 Differences in basement membrane zone components of normal conjunctiva, conjunctiva in glaucoma and normal skin
Messmer EM; Valet VM; Kampik A
Acta Ophthalmologica 2012; 90: e476-e481
51341 Conjunctival inflammation in patients under topical glaucoma treatment with indication to surgery
Furtado JM; Paula JS; Soares EG; Dhegaide NH; Rocha EM; Donadi E; Rodrigues Mde L
Acta cirúrgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia 2012; 27: 732-735
50883 The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease
Labbé A; Alalwani H; Van Went C; Brasnu E; Georgescu D; Baudouin C
Investigative Ophthalmology and Visual Science 2012; 53: 4926-4931
51253 Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
Inoue K; Iwasa M; Wakakura M; Tomita G
Clinical Ophthalmology 2012; 6: 1315-1319
51391 Efficacy and Tolerability of Preservative-free Tafluprost 0.0015 % in the Treatment of Glaucoma and Ocular Hypertension
Karhanová M; Mlčák P; Fryšák Z; Marešová K
Česka a Slovenska Oftalmologie 2012; 68: 150-155
50884 Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets
Nakagawa S; Usui T; Yokoo S; Omichi S; Kimakura M; Mori Y; Miyata K; Aihara M; Amano S; Araie M
Investigative Ophthalmology and Visual Science 2012; 53: 5154-5160
51162 Design of an implantable device for ocular drug delivery
Lee JH; Pidaparti RM; Atkinson GM; Moorthy RS
Journal of Drug Delivery 2012; 2012: 527516
51044 Investigation of surfactants suitable for stabilizing of latanoprost
Ochiai A; Ohkuma M; Danjo K
International Journal of Pharmaceutics 2012; 436: 732-737
50989 Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application
Lütfi G; Müzeyyen D
Pharmaceutical Development and Technology 2013; 18: 701-709
51140 Characterisation of ilomastat for prolonged ocular drug release
Parkinson G; Gaisford S; Ru Q; Lockwood A; Khalili A; Sheridan R; Khaw PT; Brocchini S; Fadda HM
AAPS PharmSciTech 2012; 13: 1063-1072
